登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Phase I Study of Umbilical Cord Blood Natural Killer (NK) Cell Therapy for Children With High-risk, R/R Neuroblastoma.
ClinicalTrials.gov 上登记的一项神经母细胞瘤开放试验,由中山大学肿瘤防治中心牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月13日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06631391,读取于 2026年11月13日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 6
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(6 项)收起清单
1 天 至 18 岁;性别:不限
登记记录的入选字段
Suffering from the following cardiovascular diseases: grade II or higher myocardial ischemia or myocardial infarction, poorly controlled arrhythmias (including QTc interval ≥450 ms for males and ≥470 ms for females); according to the NYHA standard (Appendix Three), class III-IV heart failure, or echocardiography indicating left ventricular ejection fraction (LVEF) <50%;
排除标准第 2 条
Bone marrow suppressive chemotherapy: At least 21 days after the last bone marrow suppressive chemotherapy (if nitrosoureas were used previously, then 42 days);
入选标准第 7 条
X-ray therapy (XRT): At least 14 days after local palliative XRT (small field port); if other substantial bone marrow (BM) irradiation is involved, including prior radioactive iodine metaiodobenzylguanidine (131I-MIBG) treatment, it must end at least 42 days ago;
入选标准第 10 条
Stem cell infusion without total body irradiation (TBI): No active graft-versus-host disease, must have ended at least 56 days after transplantation or stem cell infusion;
入选标准第 11 条
Karnofsky (≥16 years old) or Lansky (<16 years old) physical status score (Appendix II) of at least 50;
入选标准第 3 条
Absolute neutrophil count (ANC) ≥1.0×10\^9/L (if bone marrow involvement, then ANC ≥0.5×10\^9/L)
入选标准第 13 条
Platelet count (PLT) ≥75×10\^9/L (if bone marrow involvement, then PLT ≥20×10\^9/L)
入选标准第 14 条
Bilirubin ≤1.5 times the upper limit of normal (ULN)
入选标准第 15 条
Creatinine ≤1.5 times ULN (calculated using the standard Cockcroft-Gault formula)
入选标准第 16 条
ALT/AST ≤3 times ULN (if there is liver metastasis, this can be relaxed to 5 times ULN)
入选标准第 17 条
Coagulation disorders (INR >1.5 or prothrombin time (PT) >ULN +4 seconds or APTT >1.5 ULN), with a tendency to bleed or currently receiving thrombolytic or anticoagulant therapy;
排除标准第 4 条
HBsAg positive and HBV DNA exceeds the upper limit of normal
排除标准第 24 条
Anti-HCV positive and HCV RNA positive
排除标准第 25 条
HIV positive
排除标准第 26 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;影像与可测量病灶;怀孕、哺乳与避孕。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06631391,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Agree to participate in the trial and sign a written informed consent form; Age ≤18 years, gender not limited; Karnofsky (≥16 years old) or Lansky (<16 years old) physical status score (Appendix II) of at least 50; Patients diagnosed with high-risk, recurrent/refractory neuroblastoma in children according to clinical diagnostic criteria, who have undergone comprehensive treatment (surgery, chemotherapy, radiotherapy ± stem cell transplantation ± GD2 monoclonal antibody therapy); Expected survival period of at least 12 weeks; The patient must have fully recovered from the acute toxic effects of all previous anticancer chemotherapy, such as recovery to grade I after bone marrow suppression; Bone marrow suppressive chemotherapy: At least 21 days after the last bone marrow suppressive chemotherapy (if nitrosoureas were used previously, then 42 days); Investigational drugs or anticancer therapies other than chemotherapy: Must not be used within 28 days before the planned start of NK cell immunotherapy. Full recovery from the clinically significant toxicity of that therapy must be confirmed; Hematopoietic growth factors: At least 14 days after the last dose of long-acting growth factors or 3 days after the last dose of short-acting growth factors; X-ray therapy (XRT): At least 14 days after local palliative XRT (small field port); if other substantial bone marrow (BM) irradiation is involved, including prior radioactive iodine metaiodobenzylguanidine (131I-MIBG) treatment, it must end at least 42 days ago; Stem cell infusion without total body irradiation (TBI): No active graft-versus-host disease, must have ended at least 56 days after transplantation or stem cell infusion; Laboratory tests during the screening period must meet the following conditions: Absolute neutrophil count (ANC) ≥1.0×10\^9/L (if bone marrow involvement, then ANC ≥0.5×10\^9/L) Platelet count (PLT) ≥75×10\^9/L (if bone marrow involvement, then PLT ≥20×10\^9/L) Bilirubin ≤1.5 times the upper limit of normal (ULN) Creatinine ≤1.5 times ULN (calculated using the standard Cockcroft-Gault formula) ALT/AST ≤3 times ULN (if there is liver metastasis, this can be relaxed to 5 times ULN) During the study period, able to comply with outpatient treatment, laboratory monitoring, and necessary clinical visits; parents/guardians of pediatric or adolescent participants are capable of understanding, consenting to, and signing the informed consent form (ICF) and applicable child assent forms before initiating any protocol-related procedures; with parental/guardian consent, the participant is capable of expressing their consent (when applicable).排除标准:Exclusion Criteria:
Symptomatic brain metastases (patients whose brain metastases have been treated and whose symptoms have been stable for more than two months prior to enrollment may be enrolled, but must be confirmed by cranial MRI, CT, or venography as having no symptoms of cerebral hemorrhage); Suffering from the following cardiovascular diseases: grade II or higher myocardial ischemia or myocardial infarction, poorly controlled arrhythmias (including QTc interval ≥450 ms for males and ≥470 ms for females); according to the NYHA standard (Appendix Three), class III-IV heart failure, or echocardiography indicating left ventricular ejection fraction (LVEF) <50%; Having a history of interstitial lung disease or suffering from interstitial lung disease at the same time; Coagulation disorders (INR >1.5 or prothrombin time (PT) >ULN +4 seconds or APTT >1.5 ULN), with a tendency to bleed or currently receiving thrombolytic or anticoagulant therapy; Arterial/venous thromboembolic events occurring within 12 months before enrollment, such as cerebrovascular accidents (including transient ischemic attacks, cerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism; Known hereditary or acquired bleeding and thrombosis tendencies (such as hemophilia patients, coagulation disorders, thrombocytopenia, splenomegaly, etc.); Long-term unhealed wounds or fractures (except pathological fractures caused by tumors); Receiving major surgery or experiencing severe traumatic injuries, fractures, or ulcers within 4 weeks before enrollment; Factors significantly affecting the absorption of oral medications, such as inability to swallow, chronic diarrhea, and intestinal obstruction; Experiencing abdominal fistula, gastrointestinal perforation, or abdominal abscess within 6 months before enrollment; Routine urine tests showing proteinuria ≥ +, and confirmed 24-hour urine protein quantification ≥1.0 g; Symptomatic serosal effusions requiring symptomatic treatment (including pleural effusion, ascites, pericardial effusion); Note: Asymptomatic serosal effusions can be enrolled, symptomatic serosal effusions after active symptomatic treatment (anticancer drugs cannot be used for treating serosal effusions), judged by the investigator to meet the enrollment criteria can be enrolled; Active infections requiring antimicrobial treatment (e.g., needing antibacterial drugs, antiviral drugs, excluding chronic hepatitis B antiviral treatment, antifungal drug treatment); History of psychoactive substance abuse that cannot be quit or has mental disorders; Participated in other antitumor drug clinical trials within 4 weeks before enrollment; Receiving systemic hormone therapy or undergoing any form of immunosuppressive therapy within 2 weeks before the first administration; In the past 2 years, suffered from active autoimmune diseases requiring systemic treatment (such as using disease-modifying drugs, corticosteroids, or immunosuppressants); Note: Substitutive treatments (such as thyroxine, insulin, or physiological corticosteroid replacement therapy for adrenal or pituitary insufficiency) do not count as systemic treatment; Contraindications for IL-2 use; Suffering from active infections requiring intravenous systemic treatment; Vaccinated with live vaccines within one month before the first use of the study drug, seasonal influenza vaccination with inactivated virus vaccines is allowed, but intranasal attenuated live influenza vaccines are not allowed; Previous or concomitant other uncured malignancies, cured skin basal cell carcinoma, cervical carcinoma in situ, and superficial bladder cancer are excluded; Other conditions judged by the investigator that may affect the conduct of the clinical study and the determination of study results; Virological tests during the screening period show any of the following: HBsAg positive and HBV DNA exceeds the upper limit of normal Anti-HCV positive and HCV RNA positive HIV positive Undergone allogeneic tissue/organ transplantation; Poor compliance, unable to cooperate with the clinical study.
引自 ClinicalTrials.gov, NCT06631391, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06631391,读取于 2026年11月13日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。